BACKGROUND: The objective of this study is to evaluate the immunogenicity of adjuvanted monovalent rabies virus (RABV)-based vaccine candidates against Ebola virus (FILORAB1), Sudan virus (FILORAB2), Marburg virus (FILORAB3), Lassa virus (LASSARAB1), and combined trivalent vaccine candidate (FILORAB1-3) and tetravalent vaccine candidate (FILORAB1-3 and LASSARAB) in nonhuman primates. METHODS: Twenty-four Macaca fascicularis were randomly assigned into 6 groups of 4 animals. Each group was vaccinated with either a single adjuvanted vaccine, the trivalent vaccine, or the tetravalent vaccine at days 0 and 28. We followed the humoral immune responses for 1 year by antigen-specific enzyme-linked immunosorbent assays and RABV neutralization assays. RESULTS: High titers of filovirus and/or Lassa virus glycoprotein-specific immunoglobulin G were induced in the vaccinated animals. There were no significant differences between immune responses in animals vaccinated with single vaccines vs trivalent or tetravalent vaccines. In addition, all vaccine groups elicited strong rabies neutralizing antibody titers. The antigen-specific immune responses were detectable for 1 year in all groups. CONCLUSIONS: In summary, this study shows the longevity of the immune responses up to 365 days for a pentavalent vaccine-against Ebola virus, Sudan virus, Marburg virus, Lassa virus, and RABV-using a safe and effective vaccine platform.
BACKGROUND: The objective of this study is to evaluate the immunogenicity of adjuvanted monovalent rabies virus (RABV)-based vaccine candidates against Ebola virus (FILORAB1), Sudan virus (FILORAB2), Marburg virus (FILORAB3), Lassa virus (LASSARAB1), and combined trivalent vaccine candidate (FILORAB1-3) and tetravalent vaccine candidate (FILORAB1-3 and LASSARAB) in nonhuman primates. METHODS: Twenty-four Macaca fascicularis were randomly assigned into 6 groups of 4 animals. Each group was vaccinated with either a single adjuvanted vaccine, the trivalent vaccine, or the tetravalent vaccine at days 0 and 28. We followed the humoral immune responses for 1 year by antigen-specific enzyme-linked immunosorbent assays and RABV neutralization assays. RESULTS: High titers of filovirus and/or Lassa virus glycoprotein-specific immunoglobulin G were induced in the vaccinated animals. There were no significant differences between immune responses in animals vaccinated with single vaccines vs trivalent or tetravalent vaccines. In addition, all vaccine groups elicited strong rabies neutralizing antibody titers. The antigen-specific immune responses were detectable for 1 year in all groups. CONCLUSIONS: In summary, this study shows the longevity of the immune responses up to 365 days for a pentavalent vaccine-against Ebola virus, Sudan virus, Marburg virus, Lassa virus, and RABV-using a safe and effective vaccine platform.
Authors: Mallory Willet; Drishya Kurup; Amy Papaneri; Christoph Wirblich; Jay W Hooper; Steve A Kwilas; Rohan Keshwara; Andrew Hudacek; Stefanie Beilfuss; Grit Rudolph; Elke Pommerening; Adriaan Vos; Andreas Neubert; Peter Jahrling; Joseph E Blaney; Reed F Johnson; Matthias J Schnell Journal: J Infect Dis Date: 2015-06-10 Impact factor: 5.226
Authors: James P McGettigan; Roger J Pomerantz; Catherine A Siler; Philip M McKenna; Heather D Foley; B Dietzschold; Matthias J Schnell Journal: J Virol Date: 2003-01 Impact factor: 5.103
Authors: Christoph Wirblich; Christopher M Coleman; Drishya Kurup; Tara S Abraham; John G Bernbaum; Peter B Jahrling; Lisa E Hensley; Reed F Johnson; Matthew B Frieman; Matthias J Schnell Journal: J Virol Date: 2017-01-03 Impact factor: 5.103
Authors: Katie A Howell; Xiangguo Qiu; Jennifer M Brannan; Christopher Bryan; Edgar Davidson; Frederick W Holtsberg; Anna Z Wec; Sergey Shulenin; Julia E Biggins; Robin Douglas; Sven G Enterlein; Hannah L Turner; Jesper Pallesen; Charles D Murin; Shihua He; Andrea Kroeker; Hong Vu; Andrew S Herbert; Marnie L Fusco; Elisabeth K Nyakatura; Jonathan R Lai; Zhen-Yong Keck; Steven K H Foung; Erica Ollmann Saphire; Larry Zeitlin; Andrew B Ward; Kartik Chandran; Benjamin J Doranz; Gary P Kobinger; John M Dye; M Javad Aman Journal: Cell Rep Date: 2016-05-05 Impact factor: 9.423
Authors: Peter D Walsh; Drishya Kurup; Dana L Hasselschwert; Christoph Wirblich; Jason E Goetzmann; Matthias J Schnell Journal: Sci Rep Date: 2017-03-09 Impact factor: 4.379
Authors: Jingjing Jiang; Stephanie J Ramos; Preeti Bangalore; Dustin Elwood; Kathleen A Cashman; Sagar B Kudchodkar; Katherine Schultheis; Holly Pugh; Jewell Walters; Jared Tur; Jian Yan; Ami Patel; Kar Muthumani; Connie S Schmaljohn; David B Weiner; Laurent M Humeau; Kate E Broderick Journal: Viruses Date: 2021-02-27 Impact factor: 5.048